ST-067 for Oral Squamous Cell Carcinoma
This study is evaluating whether a drug called ST-067 can be safely given to people with cancer.
See full descriptionAbout the trial for Oral Squamous Cell Carcinoma
Treatment Groups
This trial involves 2 different treatments. ST-067 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 8 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether ST-067 will improve 3 primary outcomes and 2 secondary outcomes in patients with Oral Squamous Cell Carcinoma. Measurement will happen over the course of At 8 weeks.
Patient Q & A Section
Who should consider clinical trials for oral squamous cell carcinoma?
Recent findings and the lack of evidence to support the use of clinical trials point to the lack of evidence to support the routine use of clinical trials for patients with oral squamous cell carcinoma.
What are common treatments for oral squamous cell carcinoma?
There is not any specific treatment to treat the oropharyngeal [head and neck cancer](https://www.withpower.com/clinical-trials/head-and-neck-cancer). Radical surgery to remove the cancer and surgery and/or radiation therapy to protect the remaining parts of the throat and neck are the common treatment options. If the cancer does not come out after an operation, radiation or chemoradiotherapy may be used to manage the cancer.
What are the signs of oral squamous cell carcinoma?
Data from a recent study has reported a range of clinical presentation of OSCC. The most common symptom of OSCC is a sore patch. Clinically suspicious skin lesions should be promptly investigated; otherwise, OSCC is difficult to diagnose on clinical grounds alone.
What is oral squamous cell carcinoma?
An effective program for oral cancer prevention and control should include education (especially for high-risk groups), access to oral health care (access to adequate oral and dental health care personnel and access to quality dental prostheses/dentures), early detection and treatment (particularly in high-risk groups), and smoking cessation.
Can oral squamous cell carcinoma be cured?
Results from a recent paper of patients in a clinical setting with a high frequency of comorbid conditions and a prolonged follow-up time showed that OSCC was difficult to cure. More information is needed about the most effective treatment for OSCC and about its curability.
How many people get oral squamous cell carcinoma a year in the United States?
Approximately 2% of all men, 7% of all women, and 8% of those 40 years and older have OSCC diagnosed over 12 months. The incidence of new diagnoses per 100,000 population in the US differs significantly by country.
What causes oral squamous cell carcinoma?
It is not clear how a small number of cases of oral squamous cell carcinoma can occur. These cases may arise as a consequence from oral infection due to the weakened immune function of the patient, or as a consequence of some cause in the environment. We recommend considering a full investigation when a child or a person presenting with oral squamous cell carcinoma presents with significant risk factors, such as tobacco use and prior radiotherapy. These risk factors are the major causes of oral squamous cell carcinoma.
How does st-067 work?
By using cell proliferation, apoptosis, and cell cycle analyses, the authors demonstrated the mechanism of St-067 in suppressing the growth of cancer cells. The study showed that St-067 inhibited the growth of oral SCC-25 cells through anti-oncogenic activity in vitro and in vivo. St-067 was also effective in both orthotopic transplant and orthotopic implant models.
What are the chances of developing oral squamous cell carcinoma?
Oral SCC is an increasingly common cancer with high rates of death. Almost 15% of oral SCC are due to exposure to tobacco, alcohol, or illicit drug use. Recent findings shows oral SCC to be unlikely to develop in patients who do not smoke, those who do not use drugs, and those who do not use drugs with a large amount of alcohol consumption (greater than four units daily). However, they must be cautious about using the test for a specific population at high risk for developing oral SCC and to be aware that a positive result does not imply that cancer will actually develop.
What are the latest developments in st-067 for therapeutic use?
The st-067 regimen is a novel treatment for locally advanced or metastatic OSCC. This regimen has had promising antitumor activity, and has been well tolerated by patients. In comparison with traditional therapies, it has a lower relapse rate, improved OS, and longer progression-free survival. Given these remarkable findings, we believe that the st-067 regimen will become the treatment of choice against advanced OSCC in the future.
What is the latest research for oral squamous cell carcinoma?
Oral squamous cell carcinoma is a [common disease in the UK(http://www.hsa.nl/) and the European countries (http://www.europe-med.info/en)] and can be [diagnosed early by screening(http://www.europe-med.info/en)--this is essential to control the disease effectively and improve the patient's quality of life and survivability with minimal side effects. Oral squamous cell carcinoma is caused by a [slow-growing(http://www.eur-lex.europa.eu/)–and–drug-resistant(http://onlinelibrary.wiley.com/doi/10.